Low-dose oral tablet manufacture for veterinary β₂-adrenergic agonist finished products is the first downstream application. Zilpaterol HCl is not approved for human use in major pharmaceutical markets, so tablet compounding is confined to registered veterinary finished pharmaceuticals or extemporaneous preparations where national prescribing frameworks permit. The hydrochloride salt is handled as a potent low-dosage active; tablet drug loads commonly fall between 0.05% w/w and 2.0% w/w, depending on target species and indication. At these concentrations, direct compression is excluded because cohesive active agglomerates segregate in the feed frame of rotary presses and because minor excipient lot-to-lot variation produces unacceptable dosage-unit non-uniformity. The standard unit-operation sequence is: pre-blending of API with a 1:10 ratio of microcrystalline cellulose through a 500 µm sieve, low-shear tumble mixing in a bin blender at 60–70% nominal volume, wet granulation with purified water or a 5% w/w povidone binder solution, wet-milling through a 1.0 mm screen, fluid-bed drying to a defined loss-on-drying endpoint, dry-milling through a 0.8 mm screen, final blending with sodium starch glycolate and magnesium stearate, and compression on a rotary tablet press with 8 mm round concave tooling. The critical process parameter is not tablet hardness but dosage-unit uniformity. Blend uniformity is sampled with a stratified powder thief at 10 locations; the acceptance criterion is relative standard deviation not more than 5.0% before and after lubrication. Finished tablets are tested against USP <905> uniformity of dosage units, and dissolution is evaluated under USP <711> using a pH 1.2 or 0.01 M hydrochloric acid medium based on discriminating power established during method development. Because the active has a narrow therapeutic index in target species, in-process tablet weight control is maintained at ±2.0% around target, and tablet friability is limited to not more than 1.0% under USP <1216>.

Rotary press speed is reduced to 20–40 rpm when flow of the final blend is marginal; this is the principal bottleneck observed on production lines handling low-dose beta-agonist granulations. If the final blend Carr index exceeds 30%, the batch is not compressed until colloidal silicon dioxide is added at 0.25–0.5% w/w. Compression force is maintained between 5 kN and 12 kN for 8 mm round concave tooling, with tablet hardness typically controlled between 30 N and 60 N. Ejection force should remain below 500 N; higher values indicate insufficient granulation dryness or excess lubricant depletion at the die wall. Tablets are packaged in high-density polyethylene bottles with heat induction seals and desiccant canisters because the hydrochloride salt is hygroscopic. Stability chambers follow ICH Q1A(R2) conditions at 25°C/60% RH and 40°C/75% RH. Release testing includes assay by high-performance liquid chromatography, related substances, dissolution, microbial limits, and residual solvents under ICH Q3C. Batch records are governed by 21 CFR 211 where the finished product is registered for veterinary use, and API handling before formulation is governed by ICH Q7.

Why Does Particle Size Distribution Control Content Uniformity in Low-Dose Capsule Blends?

Capsule filling of zilpaterol HCl presents a different segregation mechanism than tablet compression. In capsule manufacture, the active is typically blended with a coarse carrier, usually lactose monohydrate with a D50 of 120–150 µm, to create an ordered mixture. The milled hydrochloride salt, with a D90 below 30 µm when required for dissolution, adheres to the carrier surface through interparticle forces; this adhesion reduces free active that could segregate during transfer. However, the ordered mixture is sensitive to triboelectric charging, overmixing, and carrier surface roughness. Overmixing in a double-cone or bin blender at speeds above 15 rpm can dislodge fine active particles from the carrier, producing a free fraction that migrates toward the bottom discharge port. The result is a batch profile in which the first filled capsules are sub-potent and the final capsules exceed the upper content-uniformity limit. Capsule filling on dosator machines is preferred over tamping-pin machines when the active is cohesive and the fill weight is below 200 mg; tamping-pin stations create localized compaction that may fracture carrier particles and release active from the ordered mixture. Process control includes periodic stratification sampling at the filling hopper, start/middle/end capsule samples, and USP <905> content-uniformity testing with an acceptance value not more than 15.0. For low-fill-weight capsules, the dosage-unit uniformity requirement applies because the active is less than 25% of the fill weight. Capsule disintegration is evaluated with USP <701>; if hydroxypropyl methylcellulose capsule shells are used, dissolution retarding may occur at low pH and must be checked in the species-specific fed-state medium. Published data for this specific configuration is limited; therefore fill speed, excipient ratio, and overmixing time are established by design-of-experiments on the actual production capsule machine rather than by direct transfer from tablet process data.

Additional capsule-specific controls include shell moisture equilibration at 40–50% RH for gelatin shells to prevent brittle fracture on high-speed filling lines. The final blend is lubricated with magnesium stearate at 0.25–0.5% w/w for less than 5 minutes; longer lubrication can reduce dissolution rate. Colloidal silicon dioxide is included at 0.25–0.5% w/w to improve flow without excessive surface area that competes for moisture. The capsule fill weight variation is monitored by automatic checkweigher with a rejection band of ±3.0%. Empty capsule shells are dedusted and rejected if split or dented; visual inspection is performed under controlled lighting at 2000–3000 lux. Cleaning validation for potent active residues is performed with swab sampling and liquid chromatography–tandem mass spectrometry, with acceptance limits calculated from permitted daily exposure and batch size under 21 CFR 211.67.

Wet Granulation Endpoint Parameters and Drying Boundaries

The shift from direct compression to wet granulation is driven by the low-dosage uniformity risk. In a high-shear granulator, impeller speed is maintained at 150–300 rpm and chopper speed at 1500–3000 rpm, with purified water or binder solution added at 5–10 g/min/kg of dry mix. The endpoint is judged by impeller torque rise of 15–25% from dry-mix baseline, by visual ball-massing, or by in-line near-infrared monitoring in equipment fitted with process analytical technology. The granulation mass is wet-milled through a 1.0 mm screen. The main process conflict is moisture: the hydrochloride salt is hygroscopic, and overdrying to below 1.0% w/w LOD can increase granule friability and generate fines that segregate during compression, while underdrying above 3.0% w/w LOD leads to picking, sticking, and high ejection forces on the tablet press. A narrow loss-on-drying window of 1.5–2.5% w/w is therefore set for most formulations. Drying in a fluid-bed dryer is controlled with inlet air temperature of 50–60°C and product temperature not exceeding 40°C. After drying, granules are milled through a 0.8 mm screen and the particle-size distribution is controlled to retain 60–80% between 150 µm and 850 µm; fines below 150 µm are limited to ≤15%. The lubricant blending step is separated because magnesium stearate at 1.0% w/w mixed for more than 5 minutes can coat the active granules and retard dissolution of a hydrophobic formulation matrix. Process analytical technology is recommended but not mandatory; where it is absent, a torque chart record is retained as part of the batch record under 21 CFR 211. The choice of granulation route is summarized in the following comparative table for low-dose beta-agonist hydrochloride APIs:

The granule drying endpoint is also cross-checked by Karl Fischer titration for water content, not solely by loss on drying, because surface moisture and bound water behave differently during high-humidity packaging. A rapid loss-on-drying moisture balance is qualified against Karl Fischer results at three levels covering 1.0%, 2.0%, and 3.0% water. Sieve analysis is performed on a sieve shaker with 150 µm, 250 µm, 500 µm, 850 µm, and 1000 µm stainless steel sieves; the platform is run at amplitude 1.5 mm for 10 minutes. Granule friability is measured by rotating a sample with glass beads in a friability apparatus for 15 minutes, then resieving to quantify the increase in fines. If fines increase by more than 5.0 percentage points, the granulation is reworked or the compression stage is stopped. Reworking of a low-dose granulation should be avoided where possible because additional milling can destroy the drug-excipient spatial arrangement that maintains blend uniformity. Batch-to-batch variance in granulation particle-size distribution is a known source of tableting downtime on commercial lines; therefore the dryer and mill are linked to a closed transfer system under isolated containment when the active is potent.

Injectable dosage-form manufacture for zilpaterol HCl is limited to jurisdictions where a parenteral veterinary product is registered or to extemporaneous preparation under veterinary control. The hydrochloride salt is dissolved in Water for Injection; the formulation pH is maintained in the acidic range of 4.0–5.5 because the free base can precipitate when pH approaches the amine transition region. Tonicity is adjusted with sodium chloride to 290–310 mOsm/kg using USP <785> osmometry. The solution is filtered through a 0.22 µm polyvinylidene fluoride membrane in a sterile filtration train; where thermal stability data support terminal sterilization, a cycle of 121°C for 15 minutes is applied, but forced degradation studies are required because beta-agonist hydrochloride salts can undergo oxidative degradation in aqueous solution. Oxygen is displaced with nitrogen in the headspace, and antioxidant compatibility is evaluated rather than assumed. If a multi-dose vial is used, antimicrobial effectiveness is demonstrated under USP <51>. Bacterial endotoxin limits are set by USP <85> and calculated from the maximum dose; for a small-volume parenteral, common limits are not more than 0.5 EU/mL. Particulate matter is controlled by USP <788> light obscuration, with acceptance of not more than 6000 particles per container at ≥10 µm and not more than 600 particles per container at ≥25 µm for containers of 100 mL or less. Vial washing and depyrogenation are done in a hot-air oven at 250°C for 30 minutes; rubber stoppers are washed and steam-sterilized separately. Container-closure integrity is verified after filling by vacuum decay or laser-based headspace analysis per USP <1207>. The principal production bottleneck on sterile filling lines is line speed reduction for manual visual inspection of drug product; semi-automatic inspection equipment is qualified with test kits containing known particle sizes, and the detection threshold is typically 100 µm. Aseptic process simulation runs are performed with 5000–10000 units per media fill, and the acceptance criterion is 0 contaminated units under EU GMP Annex 1 and current FDA guidance. Because published data for this specific zilpaterol HCl parenteral configuration is limited, compatibility with stopper coatings and the final pH range must be confirmed by extractables and leachables studies under ICH Q3D and USP <1663>.

Terminal sterilization can be evaluated only after thermal cycling in the final container. Aqueous zilpaterol HCl solutions may show pH drift during autoclaving if the container glass hydrolyzes at high temperature; Type I borosilicate glass vials and fluoropolymer-coated chlorobutyl stoppers reduce this risk. The fill volume is checked by in-line weight or capacitive monitoring, with a target overfill of 0.15–0.3 mL for a 10 mL single-dose vial to allow withdrawal volume. Filter integrity is tested before and after filling by bubble point or pressure decay, with the specific membrane manufacturer’s acceptance limits. The production area is certified under ISO 5 for critical zones and ISO 7 for background rooms; air velocity is maintained at 0.36–0.54 m/s in unidirectional airflow. Personnel qualification includes gowning certification and gloved-fingertip sampling per current sterility assurance guidance. The final product is tested for sterility under USP <71>, bacterial endotoxins under USP <85>, and leachables when the container closure is non-standard. If the product is lyophilized, the freeze-drying cycle must be designed around the glass transition temperature of the formulation; published data for this specific configuration is limited and cycle development is based on thermal analysis.

When Oral Granules Are Loaded onto Pregelatinized Starch Carriers for Sachet Filling

Oral granule formulations are used where tablets and capsules are difficult to administer to cattle or other target species. A low-dose zilpaterol HCl granulation is produced by top-spray fluid-bed granulation onto a pregelatinized starch or mannitol carrier. The spray rate is adjusted to maintain product temperature between 28°C and 34°C; inlet air temperature is set at 50–65°C and inlet air dew point is controlled below 10°C to prevent premature binder activation. The binder is typically hydroxypropyl cellulose at 3–5% w/w sprayed as an aqueous solution. After granulation, the product is dried to a loss-on-drying of ≤2.5% w/w, then passed over a 850 µm screen to remove oversized granules and a 150 µm screen to remove fines. The retained granule fraction should represent 70–85% of total yield. Sachet filling is performed with auger or volumetric fillers. Fill weight variation is controlled to ±5.0% for unit doses below 1 g; seal integrity is evaluated by vacuum decay under ASTM F2338-09 and peel strength with a tensile tester following ASTM F88/F88M-21. Because the active is an amine hydrochloride, the formulation should avoid reducing sugars such as lactose or dextrose in the liquid reconstitution vehicle if prolonged storage occurs; amine-carbonyl condensation can reduce assay and produce colored degradation products. The granules are administered after reconstitution in water or top-dressed onto feed. If the product is intended for in-feed top-dressing, cross-contamination control in the feed mill is managed by segregating medicated and non-medicated lines and by cleaning validation with swab limits calculated under 21 CFR 211.67 for registered veterinary drugs. The sachet format does not eliminate the need for content-uniformity testing; the granule blend is sampled at 10 locations and tested according to USP <905> or the equivalent finished-product dosage unit method.

Sachet packaging material is typically a laminated low-density polyethylene/aluminium foil/polyethylene terephthalate film with a water vapor transmission rate below 0.1 g/m²/day; desiccant is added for products distributed in humid zones. Granule particle-size distribution is assessed by sieve analysis; the finished sachet is also tested for moisture content and related substances. For oral administration, the granule is reconstituted in a specific volume of potable water in a graduated dosing device, and the mixture is used immediately. Long hold times after reconstitution may cause pH drift and free-base precipitation if the vehicle is alkaline; water quality should be controlled because hard water containing high levels of divalent cations may reduce dissolution or form insoluble salts with certain anionic excipients. Published data for this specific zilpaterol HCl granule configuration is limited; preformulation compatibility is confirmed by binary API-excipient studies at 40°C/75% RH in open containers for 4 weeks. Design of experiments for fluid-bed process parameters includes spray rate, inlet temperature, atomization air pressure, and product bed depth, with response variables of granule size, loss on drying, and content uniformity.

Residue Control and Analytical Reference Applications

Zilpaterol HCl also enters downstream analytical programs as a certified reference material for the detection and quantification of beta-agonist residues in edible bovine tissues. Regulatory food-safety laboratories use the hydrochloride salt to prepare matrix-matched calibrators in liver, muscle, kidney, and fat. Published LC-MS/MS procedures typically employ electrospray ionization with selected reaction monitoring; reported lower limits of quantification vary by matrix and extraction protocol, but methods in the literature frequently achieve values below 0.1 µg/kg for liver and muscle. Extraction may involve enzymatic hydrolysis with beta-glucuronidase/arylsulfatase, clean-up by solid-phase extraction, and quantification against isotope-labeled internal standards. Laboratory operations are accredited under ISO/IEC 17025:2017, and method validation follows Commission Decision 2002/657/EC for confirmatory methods. The reference material itself is handled as a low-moisture, light-protected solid; storage at 2–8°C in a desiccated amber container is typical, and reconstituted stock solutions should be assessed for photolytic and hydrolytic degradation because signal suppression can occur with aged stock solutions. This downstream use is not a dosage-form application but is part of the veterinary safety chain. The following checklist summarizes compliance anchors for analytical release of this compound as a reference standard:

Certificates of analysis for the reference standard include identity by infrared spectroscopy, assay by quantitative HPLC, water content by Karl Fischer titration, residual solvents by headspace gas chromatography under ICH Q3C, and related substances at a reporting threshold of 0.05%. Where stereochemical identity is relevant for bioactivity, the analytical standard may require enantiomeric purity or diastereomeric purity testing by chiral HPLC; public specifications vary by supplier. The standard is used as a primary calibrant for quantifier and qualifier ion transitions in mass spectrometric methods; stock standard stability is monitored by comparing peak area ratios at 2–8°C, -20°C, and room temperature over a defined study interval. Laboratories should not rely on nominal concentration claims without verification; accreditation under ISO/IEC 17025:2017 requires documented metrological traceability and uncertainty budgets for the stock standard preparation. Published data for this specific configuration is limited in the public domain because residue method details are often embedded in national monitoring program reports. The final output of such programs is the analytical result, not a finished pharmaceutical dosage form, and the material is therefore packaged in small sealed units under inert gas to prevent oxidative and hydrolytic deterioration during laboratory storage.